CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.

# JPMorgan Investor Forum Amsterdam

May 13, 2016



#### Our motivation in numbers – Q1 2016

Every 0.7 seconds we provide a dialysis treatment somewhere on the globe in one of our dialysis clinics.



# Business case












# Expected development of global dialysis patient population


Expected patient growth of around 6% p.a.

Driven by age, lifestyle and higher life expectancy






### Dialysis services worldwide – Number of patients treated<sup>1</sup>






### -Market position by major product groups 2015

	Position 1
Dialyzers	FMC
Dialysis machines	FMC
Hemodialysis concentrates	FMC
Bloodlines	FMC
Peritoneal dialysis products	Baxter





#### Global presence: products & services







Q1 2016






### Strong start to the year

#### Q1 2016 Highlights

- Strong growth in group revenue and net income
- Excellent development in North American business
- EMEA, Asia Pacific and Latin America impacted by foreign currency headwinds
- Care Coordination with good organic growth
- First quarter performance in line to achieve full year guidance

#### Q1 2016 Performance (US\$ million)






Diagrams: different scales applied

### Solid organic growth in all regions

North America	US\$ million	
Revenue	3,044	+10%
Organic growth		+7%



US\$ million	
1,158	+7%cc
	+7%
631	+5%cc
	+4%
374	+10%cc
	+11%
153	+5%cc
	+12%
	1,158

cc = constant currency, corporate revenue = \$3m



### Taking care of patients through global footprint



Providing care to over 294,000 patients (+2%):

North America	~ 183,000
EMEA	~ 55,000
Latin America	~ 29,000
Asia-Pacific	~ 27,000

	Clinics	De novo	Acquired
	as of Mar 31, 2016	Q1 2016	Q1 2016
Total	3,432	+22	+6
Growth year on year	+1%		
North America	2,224	+10	+6
Growth year on year	+2%		
EMEA, Latin America, Asia-Pacific	1,208	+12	-
Growth year on year	-		






### -Health Care revenue continues to grow

Total Health Care	3,414	3,182	7	9	7
EMEA, Asia-Pacific, Latin America	582	611	(5)	6	7
of which Care Coordination	522	434	20	20	17
North America	2,832	2,571	10	10	8
	<b>Q1 2016</b> US\$ million	<b>Q1 2015</b> US\$ million	Growth in %	Growth in %cc	Organic growth in %

- ▶ 5% increase in dialysis treatments
- Higher revenue supported by favorable payer development
- Care Coordination with good organic growth





cc = constant currency



### Dialysis Products show good demand

	<b>Q1 2016</b> US\$ million	<b>Q1 2015</b> US\$ million	Growth in %	Growth in %cc
North America	212	200	6	6
EMEA, Asia-Pacific, Latin America	576	569	1	8
Corporate	3	9	(63)	(62)
Total Dialysis Products	791	778	2	6

- Increased sales of dialyzers, machines and bloodlines
- Solid growth despite strong comparable first half 2015
- Foreign currency headwinds outside North America
- Global PD growth at 4% yoy (cc);
   North American PD growth at 15% yoy





Financials & outlook





### Profit grows faster than top line

	<b>Q1 2016</b> in \$ million	Q1 2015 in \$ million	Growth in %
Net revenue	4,205	3,960	6
Operating income (EBIT)	540	504	7
EBIT-margin in %	12.8	12.7	(10bp)
Net interest expense	105	102	3
Income before taxes	435	402	8
Income tax expense	138	138	-
Tax rate in %	31.8	34.4	(250bp)
Non-controlling interest	69	54	25
Net income	228	210	9


Revenue increased by 9% constant-currency, in line with full-year guidance

- Lower income tax expense due to increased noncontrolling interest in the US and lower tax rates in certain tax jurisdictions
- Net income supported by lower cost for healthcare supplies and savings from Global Efficiency Program





### -North America again with strong margin increase



FRESENIUS MEDICAL CARE \*excl. Corporate

### Cash flow development and credit profile

Days sales outstanding (DSO) at 74 days worldwide.	<b>Q1 2016</b> in \$ million	<b>Q1 2015</b> in \$ million
Operating cash flow	180	447
in % of revenue	4.3	11.3
Capital expenditures, net	(246)	(197)
Free cash flow	(66)	250
Free cash flow, after acquisitions and investments	(157)	239



Total debt/EBITDA-ratio

#### **Current ratings**

	S&P	Moody's	Fitch
Company	BBB-	Ba1	BB+
Outlook	stable	stable	stable

A reconciliation to the most directly comparable U.S. GAAP financial measures is provided in the attachments.






Outlook confirmed				
	2016 Outlook			
Revenue growth	+ 7 to 10% cc			
Net income growth	+15 to 20%			
Assumptions:				
<ul> <li>2016 net income growth outlook is based on c</li> </ul>	urrent exchange rates			
Savings from the Global Efficiency Program are included				
Acquisitions 2015/2016 are not included				
Net income growth based on US\$ 1,057 million in 2015				

cc = constant currency




© | May 2016 18

#### 2020 growth strategy









#### -Why Care Coordination?


2020 target of \$28bn of revenue ... high single digit EAT growth

Our focus is chronically ill patients; by coordinating the network and organizing care, we can actively manage the medical cost Value-based care in the U.S. is a reality. This environment helps us drive forward our care coordination strategy and developed markets around the world are adapting in their own way

Care Coordination is the only way to manage high cost chronic illness



#### The Key to success



- National provider networkGeography
- Diversified participation in value-based care
- Experience & expertise
- Care navigation
- Evidence-based protocols
- Research
- Process design
  Data analytics
  Technology




3

## Back-up



#### -Day sales outstanding (DSO)





### Patients, treatments, clinics

	<b>Clinics</b> as of Mar. 31, 2016	Patients as of Mar. 31, 2016	<b>Treatments</b> Q1 2016, in million
North America	2,224	182,808	7.1
Growth in %	2	3	6
EMEA	658	55,197	2.1
Asia-Pacific	323	26,713	1.0
Latin America	227	29,325	1.2
Total	3,432	294,043	11.3
Growth in %	1	2	5



-Fxcha	Exchange rates					
Exchange rates		Q1 2015	FY 2015	Q1 2016		
€:\$	Period end	1.0759	1.0887	1.1385		
	Average	1.1261	1.1095	1.1020		
\$:CNY	Period end	6.2004	6.4855	6.4571		
	Average	6.2367	6.2851	6.5427		
\$:RUB	Period end	58.0351	74.1009	67.0225		
	Average	63.0147	61.3538	74.8191		
\$:ARS	Period end	8.8095	12.9825	14.6423		
	Average	8.6890	9.2570	14.4491		



U.S. dialysis days per quarter						
	Q1	Q2	Q3	Q4	Full year	
2014	76	78	79	80	313	
2015	76	78	79	79	312	
2016	78	78	79	79	314	
2017	77	78	79	78	312	



**Safe harbor statement**: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views with respect to future events an financial performance. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA independent of being the reported or the adjusted number. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in US-\$ if not mentioned otherwise.



**Constant currency:** Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "at constant exchange rates" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. Under U.S. GAAP, revenues received in local (non-U.S. dollar) currency are translated into U.S. dollars at the average exchange rate for the period presented. When we use the term "constant currency," it means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. We then calculate the change, as a percentage, of the current period revenues using the prior period exchange rates versus the prior period revenues. This resulting percentage is a non-GAAP measure referring to a change as a percentage "at constant exchange rates."

We believe that revenue growth is a key indication of how a company is progressing from period to period and that the non-GAAP financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on its revenue from period to period. However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-U.S. GAAP revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue prepared in accordance with U.S. GAAP revenue. Because the reconciliation derived from U.S. GAAP revenue next to the fluctuation derived from non-GAAP revenue. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.



### -Financial calendar \*

May 12, 2016Annual General Meeting, FrankfurtAugust 2, 2016Q2 2016 results

October 27, 2016 Q3 2016 results

May 13, 2016	J.P. Morgan Cazenove Amsterdam Investor Forum
May 24, 2016	Berenberg European Conference USA
May 25, 2016	UBS Global Healthcare Conference NY
May 30, 2016	Danske German Corporate Day Copenhagen
May 31, 2016	Kepler Cheuvreux One-Stop-Shop Geneva

\* Please note that dates and/or participation might be subject to change



#### Contacts

**FME Investor Relations** Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany

WKN: ISIN:

Ticker: FME or FMS (NYSE) 578 580 DE00057858002

#### **Oliver Maier**

Head of Investor Relations and **Corporate Communications** Tel: +49-(0) 6172-609-2601 Email: <u>oliver.maier@fmc-ag.com</u>

#### **Robert Adolph**

**Director Investor Relations** Tel.: +49-(0) 6172-609-2477 Email: robert.adolph@fmc-ag.com

#### Juliane Beckmann

Senior Manager Investor Relations Tel.: +49-(0) 6172-609-5216Email: juliane.beckmann@fmc-ag.com

#### **Terry Morris**

**VP Investor Relations North America** Tel: +1-800-948-2538 Email: terry.morris@fmc-na.com





CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.

# JPMorgan Investor Forum Amsterdam

May 13, 2016

